Zeno Dock News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: May 13, 2021 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ®), today announced new collaborations in Israel, Italy and Spain to expand molecular screening opportunities for patients with cancers that may have neuregulin 1 (NRG1) fusions and to raise awareness of the Merus eNRGy clinical trial of its bispecific antibody zenocutuzumab (Zeno). In the collaborations, Merus plans to support molecula...

(2) UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 28, 2021. (Nasdaq: MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced the company's selection for oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4-8, 2021. The presentation highlights updated interim clinical data for the targeted bispecific antibody, zenocutuzumab (Zeno), in NRG1 fusion positive (NRG1+) cancers. Merus is currently recruiti...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Association ... Merus N.V.March 10, 2021 GMT UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Merus will present preclinical data from our zenocutuzumab and...

(2) UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 10, 2021(Nasdaq: MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Merus will present preclinical data from our zenocutuzumab and MCLA-129 programs in three poster presentations at the American Association for Cancer Research 2021 Annual Meeting being held virtually for two weeks, April 10-15, 2021 and May 17-21, 2021. E-Poster Presentation: Title: The HER2×HER3 bi-specific antibody zenocutuzumab...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and ... Merus N.V.January 12, 2021 GMT UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced collaborations with nationwide medical organizations in the Netherlands and Japan to raise awareness of the eNRGy trial and...